Human mesenchymal stem cells differentiate into an osteogenic lineage in presence of strontium containing bioactive glass nanoparticles
Source abstract
Abstract
While bioactive glass and ions released during its dissolution are known to stimulate osteoblast cells, the effect bioactive glass has on human stem cells is not clear. Here, we show that spherical monodispersed strontium containing bioactive nanoparticles (Sr-BGNPs) of composition 90.6 mol% SiO2, 5.0 mol% CaO, 4.4% mol% SrO (4.4%Sr-BGNPs) and 88.8 mol% SiO2, 1.8 mol% CaO, and 9.4 mol% SrO (9.4%Sr-BGNPs) stimulate bone marrow derived human stem cell (hMSC) differentiation down an osteogenic pathway without osteogenic supplements. The particles were synthesised using a modified Stӧber process and had diameters of 90 ± 10 nm. Previous work on similar particles that did not contain Sr (80 mol% SiO2, 20 mol% CaO) showed stem cells did not differentiate when exposed to the particles. Here, both compositions of the Sr-BGNPs (up to concentration of 250 μg/mL) stimulated the early-, mid-, and late-stage markers of osteogenic differentiation and accelerated mineralisation in the absence of osteogenic supplements. Sr ions play a key role in osteogenic stem cell differentiation. Sr-BGNP dissolution products did not adversely affect hMSC viability and no significant differences in viability were measured between each particle composition. Confocal and transmission electron microscopy (TEM) demonstrated that monodispersed Sr-BGNPs were internalised and localised within vesicles in the cytoplasm of hMSCs. Degradation of particles inside the cells was observed, whilst maintaining effective cations (Ca and Sr) in their silica network after 24 h in culture. The uptake of Sr-BGNPs by hMSCs was reduced by inhibitors of specific routes of endocytosis, indicating that the Sr-BGNPs uptake by hMSCs was probably via mixed endocytosis mechanisms. Sr-BGNPs have potential as injectable therapeutic devices for bone regeneration or treatment of conditions such as osteoporosis, because of their ability deliver a sustained release of osteogenic inorganic cations, e.g. calcium (Ca) or and strontium (Sr), through particle degradation locally to cells. STATEMENT OF SIGNIFICANCE: Here, we show that 90 nm spherical strontium containing bioactive nanoparticles of stimulate bone marrow derived human stem cell (hMSC) differentiation down an osteogenic pathway without the use of osteogenic supplements. While bioactive glass and its dissolution products are known to promote excellent bone regeneration in vivo and to stimulate osteoblast cells to produce bone matrix in vitro, their effect on human stem cells is not clear. Previously our nanoparticles that contained only SiO2 and CaO did not provoke human bone marrow or adipose derived stem cell differentiation.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Laser-Ablation Synthesis of Nanoparticles · Dental Implant Techniques and Outcomes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. The cost of osteoporotic fractures in the UK: projections for 2000–202010.3111/200104051062 ↗
2. Osteoporosis in the European Union: a compendium of country-specific reports10.1007/s11657-013-0137-0 ↗
3. Geographic and ethnic disparities in osteoporotic fractures, Nature reviews
4. The worldwide problem of osteoporosis: insights afforded by epidemiology10.1016/8756-3282(95)00258-4 ↗
5. Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group10.7326/0003-4819-115-11-837 ↗
6. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–202510.1359/jbmr.061113 ↗
7. Incorporation and distribution of strontium in bone10.1016/S8756-3282(01)00419-7 ↗
8. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy10.1007/s00198-007-0540-8 ↗
9. Bisphosphonates: mechanism of action and role in clinical practice10.4065/83.9.1032 ↗
10. Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties10.1038/srep43399 ↗
11. Recent advances in understanding the mechanism of action of bisphosphonates10.1016/j.coph.2006.03.005 ↗
12. Effects of bisphosphonates on matrix mineralization
13. The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density10.1302/2046-3758.610.BJR-2016-0321.R1 ↗
14. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study10.1007/s00198-008-0805-x ↗
15. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate10.1056/NEJMc0707493 ↗
16. Bisphosphonates and atypical subtrochanteric fractures of the femur10.1302/2046-3758.63.BJR-2016-0125.R1 ↗
17. Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance10.1073/pnas.1704460114 ↗
18. Osteoporosis – a current view of pharmacological prevention and treatment
19. Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal
20. Strontium and strontium ranelate: Historical review of some of their functions10.1016/j.msec.2017.05.042 ↗
21. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis10.1007/s00198-011-1847-z ↗
22. Strontium ranelate in osteoporosis10.2174/1381612023393639 ↗
23. Strontium ranelate for preventing and treating postmenopausal osteoporosis
24. Ten years too long: strontium ranelate, cardiac events, and the European Medicines Agency
25. Strontium ranelate in osteoporosis and beyond: identifying molecular targets in bone cell biology10.1124/mi.10.5.7 ↗
26. Dual effect of strontium ranelate: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro10.1016/j.bone.2007.08.043 ↗
27. Osteoblasts play key roles in the mechanisms of action of strontium ranelate10.1111/j.1476-5381.2009.00305.x ↗
28. In vitro effects of strontium ranelate on the extracellular calcium-sensing receptor10.1016/j.bbrc.2004.08.209 ↗
29. The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways10.1074/jbc.M801668200 ↗
30. A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record
31. Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD10.1007/s00198-013-2582-4 ↗
32. Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate10.1007/s00198-013-2469-4 ↗
33. Bioglass and bioactive glasses and their impact on healthcare10.1111/ijag.12252 ↗
34. Bonding mechanisms at the interface of ceramic prosthetic materials10.1002/jbm.820050611 ↗
35. Opening paper 2015-some comments on bioglass: four eras of discovery and development10.1515/bglass-2015-0001 ↗
36. Gene-expression profiling of human osteoblasts following treatment with the ionic products of Bioglass 45S5 dissolution10.1002/1097-4636(200105)55:2<151::AID-JBM1001>3.0.CO;2-D ↗
37. Gene activating glasses
38. Ionic products of bioactive glass dissolution increase proliferation of human osteoblasts and induce insulin-like growth factor II mRNA expression and protein synthesis10.1006/bbrc.2000.3503 ↗
39. Interactions of bioactive glasses with osteoblasts in vitro: effects of 45S5 Bioglass, and 58S and 77S bioactive glasses on metabolism, intracellular ion concentrations and cell viability10.1016/S0142-9612(00)00173-3 ↗
40. Differentiation of fetal osteoblasts and formation of mineralized bone nodules by 45S5 Bioglass® conditioned medium in the absence of osteogenic supplements10.1016/j.biomaterials.2009.03.019 ↗
41. Spherical bioactive glass particles and their interaction with human mesenchymal stem cells in vitro10.1016/j.biomaterials.2010.08.082 ↗
42. Monodispersed strontium containing bioactive glass nanoparticles and MC3T3-E1 cellular response10.1515/bglass-2016-0009 ↗
43. In vitro osteogenesis by intracellular uptake of strontium containing bioactive glass nanoparticles10.1016/j.actbio.2017.11.008 ↗
44. Monodisperse photoluminescent and highly biocompatible bioactive glass nanoparticles for controlled drug delivery and cell imaging10.1039/C5TB00204D ↗
45. Bioactive glass nanoparticles: from synthesis to materials design for biomedical applications10.3390/ma9040288 ↗
46. Intrinsic ultrahigh drug/miRNA loading capacity of biodegradable bioactive glass nanoparticles toward highly efficient pharmaceutical delivery10.1021/acsami.6b13874 ↗
47. Si3N4-bioglass composites stimulate the proliferation of MG63 osteoblast-like cells and support the osteogenic differentiation of human bone marrow cells10.1016/S0142-9612(02)00249-1 ↗
48. Bioactive nanoparticles stimulate bone tissue formation in bioprinted three-dimensional scaffold and human mesenchymal stem cells10.1002/biot.201400305 ↗
49. In vitro proliferation and differentiation of human bone marrow mesenchymal stem cells into osteoblasts on nanocomposite scaffolds based on bioactive glass (64SiO2-31CaO-5P2O5)-poly-l-lactic acid nanofibers fabricated by electrospinning method10.1016/j.msec.2017.02.165 ↗
50. Osteogenic potential of stem cells-seeded bioactive nanocomposite scaffolds: A comparative study between human mesenchymal stem cells derived from bone, umbilical cord Wharton's jelly, and adipose tissue10.1002/jbm.b.33814 ↗
51. The influence of strontium release rate from bioactive phosphate glasses on osteogenic differentiation of human mesenchymal stem cells10.1016/j.jeurceramsoc.2017.08.005 ↗
52. Sparse feature selection methods identify unexpected global cellular response to strontium-containing materials10.1073/pnas.1419799112 ↗
53. The effect of bioactive glasses on bone marrow stromal cells differentiation10.1016/j.biomaterials.2004.09.059 ↗
54. Differential alkaline phosphatase responses of rat and human bone marrow derived mesenchymal stem cells to 45S5 bioactive glass10.1016/j.biomaterials.2007.05.038 ↗
55. Coating of VEGF-releasing scaffolds with bioactive glass for angiogenesis and bone regeneration10.1016/j.biomaterials.2006.01.033 ↗
56. Monodispersed bioactive glass submicron particles and their effect on bone marrow and adipose tissue-derived stem cells10.1002/adhm.201300126 ↗
57. The incorporation of 70s bioactive glass to the osteogenic differentiation of murine embryonic stem cells in 3D bioreactors10.1002/term.135 ↗
58. Enhanced derivation of osteogenic cells from murine embryonic stem cells after treatment with ionic dissolution products of 58S bioactive sol-gel glass10.1089/ten.2005.11.479 ↗
59. Bioactive glass ions as strong enhancers of osteogenic differentiation in human adipose stem cells10.1016/j.actbio.2015.04.017 ↗
60. Bioactive glass induced osteogenic differentiation of human adipose stem cells is dependent on cell attachment mechanism and mitogen-activated protein kinases10.22203/eCM.v035a05 ↗
61. Influence of calcium and phosphorus release from bioactive glasses on viability and differentiation of dental pulp stem cells10.1007/s10853-017-0946-4 ↗
62. The osteogenic response of mesenchymal stromal cells to strontium-substituted bioactive glasses10.1002/term.2003 ↗
63. Strontium enhances osteogenic differentiation of mesenchymal stem cells and in vivo bone formation by activating Wnt/Catenin signaling10.1002/stem.646 ↗
64. Osteoconductivity of strontium-doped bioactive glass particles: A histomorphometric study in rats10.1002/jbm.a.32355 ↗
65. Three-dimensional printed strontium-containing mesoporous bioactive glass scaffolds for repairing rat critical-sized calvarial defects10.1016/j.actbio.2014.10.015 ↗
66. The effects of strontium-substituted bioactive glasses on osteoblasts and osteoclasts in vitro10.1016/j.biomaterials.2010.01.121 ↗
67. Effects of strontium-doped bioactive glass on the differentiation of cultured osteogenic cells10.22203/eCM.v021a11 ↗
68. Strontium-substituted submicrometer bioactive glasses modulate macrophage responses for improved bone regeneration10.1021/acsami.6b10378 ↗
69. Synergistic effect of strontium and silicon in strontium-substituted sub-micron bioactive glass for enhanced osteogenesis10.1016/j.msec.2018.04.012 ↗
70. The synergistic effects of Sr and Si bioactive ions on osteogenesis, osteoclastogenesis and angiogenesis for osteoporotic bone regeneration10.1016/j.actbio.2017.08.015 ↗
71. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement10.1080/14653240600855905 ↗
72. Mesenchymal progenitors able to differentiate into osteogenic, chondrogenic, and/or adipogenic cells in vitro are present in most primary fibroblast-like cell populations10.1634/stemcells.2006-0504 ↗
73. Multilineage potential of adult human mesenchymal stem cells10.1126/science.284.5411.143 ↗
74. Nanoparticles for live cell microscopy: A surface-enhanced Raman scattering perspective10.1038/s41598-017-04066-0 ↗
75. Intracellular fate of spherical nucleic acid nanoparticle conjugates10.1021/ja503010a ↗
76. Identification of differentiation-stage specific markers that define the ex vivo osteoblastic phenotype10.1016/j.bone.2014.06.027 ↗
77. The gene-expression and phenotypic response of hFOB 1.19 osteoblasts to surface-modified titanium and zirconia10.1016/j.biomaterials.2008.10.054 ↗
78. Gene expression profiling of human mesenchymal stem cells for identification of novel markers in early- and late-stage cell culture10.1093/jb/mvn082 ↗
79. The role of nanofibrous structure in osteogenic differentiation of human mesenchymal stem cells with serial passage10.2217/nnm.11.26 ↗
80. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion10.1128/MCB.25.19.8581-8591.2005 ↗
81. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha10.1074/jbc.M106339200 ↗
82. Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells10.1359/jbmr.2003.18.2.213 ↗
83. Minireview: transcriptional control of osteoblast differentiation10.1210/endo.142.7.8306 ↗
84. Osteogenic programming of human mesenchymal stem cells with highly efficient intracellular delivery of RUNX210.1002/sctm.17-0137 ↗
85. Modulation of osteogenesis in human mesenchymal stem cells by specific pulsed electromagnetic field stimulation10.1002/jor.20862 ↗
86. Development of the osteoblast phenotype: molecular mechanisms mediating osteoblast growth and differentiation
87. A novel collagen scaffold supports human osteogenesis—applications for bone tissue engineering10.1007/s00441-010-0939-y ↗
88. Gene expression pattern during osteogenic differentiation of human periodontal ligament cells in vitro10.5051/jpis.2011.41.4.167 ↗
89. Preparation of poly(ethylene glycol)/polylactide hybrid fibrous scaffolds for bone tissue engineering
90. Endocytic mechanisms of graphene oxide nanosheets in osteoblasts, hepatocytes and macrophages10.1021/am5031598 ↗
91. The effect of nanoparticle size, shape, and surface chemistry on biological systems10.1146/annurev-bioeng-071811-150124 ↗
92. Insights into cellular uptake of nanoparticles10.2174/1567201811666140821110631 ↗
93. Nanoparticles: cellular uptake and cytotoxicity
94. Endocytosis and exocytosis of nanoparticles in mammalian cells
95. Effect of size on the cellular endocytosis and controlled release of mesoporous silica nanoparticles for intracellular delivery10.1007/s10544-011-9604-9 ↗
96. Mesoporous silica nanoparticles as nanocarriers10.1039/c1cc11760b ↗
97. Highly efficient cellular labeling of mesoporous nanoparticles in human mesenchymal stem cells: implication for stem cell tracking10.1096/fj.05-4288fje ↗
98. The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells10.1016/j.biomaterials.2007.03.006 ↗
99. Mesenchymal stem cells: clinical applications and biological characterization10.1016/j.biocel.2003.11.001 ↗
100. Human bone cell cultures in biocompatibility testing. Part II: effect of ascorbic acid, β-glycerophosphate and dexamethasone on osteoblastic differentiation10.1016/S0142-9612(99)00192-1 ↗